AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05989542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1001
Description: 200mg BID Oral
Study NCT05293574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norethisterone acetate
Description: Norethindrone, a progesterone agonist
Study NCT05753098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrogen therapy
Description: oral estradiol valerate
Study NCT05753098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: PDE5 inhibitor
Study NCT05753098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 50mg
Description: used for ovulation induction
Study NCT05753098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: used for ovulation induction
Study NCT05480826 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: study of the transmission of genetic variants
Description: the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
Study NCT06414239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a VR mask
Description: Virtual reality mask
Study NCT06414239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Without any premedication or anesthesia
Study NCT04929938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
Study NCT04929938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
Study NCT05215080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Formula Milk
Description: Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
Study NCT05322278 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: No interventions
Study NCT05321940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
Description: Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
Study NCT05321940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: 15-20 Million mature dendritic cells per dose administered via intravenous injection.
Study NCT04880850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
Study NCT04880850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
Study NCT04880850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
Study NCT04880850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
Study NCT05928637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745, D759, D150
Description: QD, PO for 5 days
Study NCT06419569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high power laser
Description: Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
Study NCT06419569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser
Description: patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
Study NCT06419569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
Study NCT06419569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
Study NCT02686203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure Laser Pro and needles
Description: Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment
Study NCT06394674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Drug: Furmonertinib
Study NCT04511052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
Study NCT04511052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
Study NCT04511052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carotenoid supplement
Description: 1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
Study NCT04511052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carotenoid supplement
Description: 1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
Study NCT04686838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READyR II: A
Description: Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
Study NCT04686838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: READyR II: B
Description: Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
Study NCT04901013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Affinity
Description: Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
Study NCT05665920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated whole breast radiotherapy
Description: Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
Study NCT05665920 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation
Description: Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
Study NCT06406517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
Study NCT06406517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobenate dimeglumine
Description: Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
Study NCT05690126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron extract
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT05690126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are taken during 6 weeks by healthy volunteers
Study NCT05495035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib, APG-2575, Dexamethasone
Description: * Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day.
Study NCT06411301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-DOTATATE
Description: Two intravenous infusions every 6 weeks (Q6W)
Study NCT06336473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
Study NCT05753670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
Study NCT05753670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
Study NCT05555368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Recovery Score
Description: Descriptive
Study NCT05485935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - intermittent catheter with micro-hole zone
Description: Intermittent male catheter with micro-hole zone for urinary drainage
Study NCT05485935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator - standard intermittent catheter
Description: SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
Study NCT05938166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral care augmented reality (AR)
Description: Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
Study NCT05142566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANTA Vascular Closure Device
Description: Evaluate the safety of ultrasound guided deployment of MANTA VCD.
Study NCT04945954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug: Cyclophosphamide
Description: Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)
Study NCT04532970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Two different types of smoking cessation counseling
Study NCT05181332 — intervention group
Intervention type: OTHER
Intervention: Prediction model
Description: Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
Study NCT04532970 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cessation Counseling
Description: Two different types of smoking cessation counseling
Study NCT05998044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Based Exercises
Description: The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch
Study NCT05998044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: They will be asked not to participate in any regular exercise for 8 weeks.
Study NCT05545709 — intervention group
Intervention type: PROCEDURE
Intervention: remote robot-assisted spine surgery
Description: Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
Study NCT06267105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Longitudinal incision
Description: Incision performed longitudinally
Study NCT06267105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse incision
Description: Incision performed transversally
Study NCT06489366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber laser (TFL) lithotripsy
Description: Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
Study NCT06489366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ho: YAG lithotripsy
Description: Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
Study NCT05964569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model-guided optimization of treatment plan
Description: original treatmant plans are optimized based on model-based NTCP
Study NCT05964569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment plan, no optimization
Description: original treatment plans are not optimized
Study NCT06344637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 % lidocaine spray without adrenaline
Description: Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
Study NCT06344637 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 puffs of normal saline apply on cervical os before manual vacuum aspiration
Study NCT04159077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax
Study NCT04159077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
Study NCT06157021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotary pulpectomy
Description: Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
Study NCT06157021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual pulpectomy
Description: Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
Study NCT04966325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200mg
Description: Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study NCT04966325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study NCT04966325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study NCT04966325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 600mg
Description: Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Study NCT04923438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
Study NCT04923438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.